Press Releases

Rice U. pursues end game for diabetes


Screen Shot 2018-10-08 at 11.18.03 AM Members of Rice’s Veiseh Lab from left: Siavash Parkhideh, Alen Trubelja, Samira Aghlara-Fotovat, Sudip Mukherjee, Omid Veiseh, Maria Ruocco, Christian Schreib and Michael Doerfert. (Photo by Jeff Fitlow, Rice University)
By riceuniversity | October 8, 2018

The National Institutes of Health backs a Rice University lab’s efforts to develop implantable “drug factories” that monitor blood glucose and release insulin on demand for patients with diabetes.

Rice University bioengineer Omid Veiseh ultimately wants patients with Type 1 diabetes to forget about it.

That’s the goal his lab has declared with funding support from the National Institutes of Health. The agency has awarded Veiseh’s lab a prestigious four-year, $2.8 million R01 grant to design hydrogel-encapsulated cells that, when placed into a patient, sense blood glucose levels and produce insulin on demand.

These on-board drug factories would eliminate the need for patients to persistently monitor their blood glucose and administer insulin shots.

“Our hope is that one day patients can be insulin-independent and not have to think about diabetes,” said Veiseh, an assistant professor of bioengineering who joined Rice in 2017. “We want to get to the point where they get the treatment and live their lives normally.”

Type 1 diabetes is an autoimmune disease, where the body’s own immune system inadvertently destroys the insulin-producing beta cells of the pancreas. Replacing the beta cells with protection from the immune system is a potential cure for many patients afflicted with this disease, Veiseh said.

To that end, his lab at Rice’s BioScience Research Collaborative is developing thousands of distinct hydrogel capsules that can protect and support pancreatic islet cells. A major challenge is developing hydrogel formulations which can hide these cells from the host immune system.

The lab’s solution involves the synthesis of 7,000 variations of hydrogels, each carrying islet cells and an individual bar code. These will allow the lab to inject multiple types of hydrogels into a small number of mice for in vivo testing.  (In vivo tests are conducted in live organisms; in vitro experiments are conducted in test tubes and the like.)

“We can’t do this in vitro, only in vivo, but it would take an army to test thousands of individual animals,” Veiseh said. Using the innovative bar coding technique, batches of different cell/capsule combinations can be implanted and those that survive the animal’s immune system can be identified based on their bar codes.

The codes themselves represent a unique approach, he said. Rather than physically marking each cell – hard to do in a jelly – or using chemical means that could induce an immune response, the researchers will encase surrogate cells along with the islet cells.

These surrogates are human umbilical vein endothelial cells. Because they’re culled from thousands of donated umbilical cords and have their donors’ distinct genomes, they can be easily identified through next-generation sequencing. That will let the lab drastically cut the amount of time it will take to test all of its variants.

“That’s going to be the first pass, and it will allow us to whittle down those 7,000 formulations to a manageable number,” Veiseh said. “Once we discover new leads, we will test those more rigorously to evaluate their ability to house and protect islet cells, and the cells’ ability to survive and correct blood glucose.” The capsules will also have to ward off fibrosis, the body’s tendency to wall off invading cells by building scar tissue.

Veiseh has been developing novel materials that enable cell-based therapies for close to a decade. He’s a co-founder of Sigilon Therapeutics, a biotech company working to commercialize this approach for treatment of various chronic diseases. He noted the development of implantable, drug-making cells is one of this year’s 10 “breakthrough” technologies listed by the World Economic Forum.

While some approaches require occasional or even frequent cell injections, Veiseh’s clear goal is to solve the complex management of diabetes for patients once and for all.

“When I started my postdoctoral research (at the Massachusetts Institute of Technology), I had a misperception that diabetes was not that big of a problem because we have insulin. But when I realized the challenges people face, particularly children, I was really inspired,” he said. “My team and I are committed to making a transformative impact for patients.”




Social Posts

profile_image

Veterans Affairs

@DeptVetAffairs

At the Vietnam Memorial, a Lake Geneva Veteran bumps into a fellow Vet he hasn't seen in 48 years https://t.co/g1Cj0rXus9 via @620wtmj

18 mins ago
profile_image

U.S. Department of Veterans Affairs

VeteransAffairs

The jumps were intended to raise awareness of Operation Enduring Warrior, a veteran-founded nonprofit organization with programs to aid wounded military and law enforcement veterans with physical and emotional rehabilitation.

49 mins ago
profile_image

MD Anderson Cancer Center

@MDAndersonNews

“This study is proof of principle that we should keep going,” says our @JenniferLitton. #immunotherapy #bcsm #endcancer https://t.co/zUbvJvOqQF

52 mins ago
profile_image

University of Houston

@UHouston

RT @UHCougarFB: 📸 | The #HTownTakeover has arrived at Navy-Marine Corps Memorial Stadium. https://t.co/difmnpTYgt

1 hour ago
profile_image

Veterans Affairs

@DeptVetAffairs

Holocaust survivors visit museum with World War II Veterans https://t.co/JJOCvMt4U6 via @ABC7News

1 hour ago
profile_image

MD Anderson Cancer Center

@MDAndersonNews

Learn how an #immunotherapy clinical trial gave #melanoma survivor Karlee Steele a chance to help other patients. #endcancer https://t.co/6OCovaOl5N

2 hours ago
profile_image

Texas Children's

@TexasChildrens

A revolutionary treatment for allergies to peanuts and other foods is going mainstream—but do the benefits outweigh the risks? Learn more via @sciencemagazine: https://t.co/NopMMWUDha #texaschildrens

2 hours ago
profile_image

BCMHouston

@bcmhouston

Congratulations to the Dr. David Persse on receiving the American College of Emergency Physician's 2018 Outstanding Contribution to EMS award. https://t.co/olQqIQpndd

2 hours ago
profile_image

University of Houston

@UHouston

RT @UHpres: It needed a little editing! https://t.co/EC9HxN05NZ

2 hours ago
profile_image

Veterans Affairs

@DeptVetAffairs

West Virginia - More space to help counsel combat Veterans https://t.co/qPgeOFv4m5 via @WVVA

2 hours ago
profile_image

CHI St. Luke's Health

@CHI_StLukes

Join us for our FREE event featuring multiple #childbirth and newborn education classes, door prizes, and a #HospitalTour. Get your tickets today: https://t.co/b8skGCLUG6 https://t.co/njd8HFqHxn

3 hours ago
profile_image

University of Houston

@UHouston

RT @UHCougarFB: ICYMI: Here's what we're wearing...⚪ Helmet ⚪ Jersey 🔴 Pants#HTownTakeover https://t.co/ONWITFNeLT

4 hours ago
profile_image

BCMHouston

@bcmhouston

Curious about cochlear implants? Join the Center for Hearing and Balance for the 3rd annual Cochlear Implant Recipient and Candidate event on Oct. 23. https://t.co/B8n6K2BsnI

4 hours ago
profile_image

TAMU Health Sciences

@TAMHSC

Rural Pharmacies Are Closing: Where Does That Leave Patients? | Patient Advice | US News https://t.co/HWf3bSegta@usnews @tamhsc_cop @rchitexas #RuralHealth #Pharmacist #Pharmacy #HealthCare #TAMHSC #AggieHealth #TAMUHealth #PatientCare https://t.co/PEDTarbxA9

4 hours ago
profile_image

MD Anderson Cancer Center

@MDAndersonNews

#Cancer can be stressful. Find out how other survivors coped with stress and anxiety during treatment: https://t.co/WJb8aWh5z4 #endcancer https://t.co/F1sHd2NZbH

4 hours ago